TOP STORIES
respiratory
Cystic fibrosis

Study supports use of ivacaftor in first year of life for children with CF


The CFTR modulator therapy ivacaftor (Kalydeco) may be safely used in the first year of life to treat the underlying cause of cystic fibrosis, latest results from the ARRIVAL study suggest. Currently listed on the PBS for use in children...

The CFTR modulator therapy ivacaftor (Kalydeco) may be safely used in the first year of life to treat the underlying...

Read more